ELTX is trading 5.59% up at $3.40 in pre-market following a turbulent stretch tied to financing updates and clinical data.
- Elicio Therapeutics recently announced a $15 million registered direct offering, which is expected to close around July 6.
- The stock has experienced recent volatility after reporting disappointing Phase 2 AMPLIFY-7P results.
- Today's upward move appears to be influenced by broader biotech sector strength and higher U.S. futures, as no fresh company-specific announcements were released this morning.